Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Fuji, Richter Strike Co-Development Pact in Women’s Health
Fuji Pharma said on March 24 that it has signed an agreement with Hungary’s Gedeon Richter to jointly develop multiple drug candidates in women’s health, including a first-in-class antibody, FMC2, for endometriosis. The partners will advance early-stage programs including FMC2,…
To read the full story
Related Article
- Fuji, Richter Expand Gynecology Partnership to Accelerate R&D
February 4, 2026
BUSINESS
- Takeda’s Zasocitinib Beats Sotyktu in PIII Psoriasis Trial
June 15, 2026
- Lilly Breaks Ground on New Building at Kobe Plant
June 15, 2026
- Shionogi Invests in Reproductive Medicine Startup Dioseve
June 15, 2026
- Chugai Files Tecentriq for Esophageal Cancer
June 15, 2026
- AbbVie Japan Files Rinvoq for Takayasu Arteritis
June 15, 2026
Japan’s pharmaceutical industry has become a global business over the past two decades. Overseas markets now make up nearly three-quarters…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…